StockData

SAB Biotherapeutics vs Scinai Immunotherapeutics

SABS and SCNI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SABS and SCNI compare

Scinai Immunotherapeutics scores higher on the StockData Score (6 against 4 for SAB Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSABSSCNI
Size and price
Market cap$268M–
Share price$2.95$0.372
Change, 1 year−9.0%−96.2%
Change, 5 years−97.2%−100.0%
Beta (5Y)1.071.20
Employees8645
StockData Score
Total score46 (better)
Valuation score1 (better)0
Growth score01 (better)
Performance score1 (better)0
Health score25 (better)
Dividend score00
Valuation
P/B1.2×–
Growth
Revenue growth (TTM)–99.2%
Net income growth (TTM)–−273%
Profitability
Gross margin–−202%
Operating margin–−575%
Net margin–−634%
FCF margin–−462%
Return on equity−11.3% (better)−84.8%
Return on invested capital−95.8%−74.7% (better)
Financial health
Debt / equity–0.00
Interest coverage−310.3×–
Current ratio9.22 (better)1.56
Altman Z-score5.47–
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions75.2%–
Held by insiders30.2%7.4%
Short interest, % of float7.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.